VIRVir Biotechnology, Inc.
What is the market doing?
No clear lean: in an uptrend, but heavily shorted (+13% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +31% vs its 200-day average.
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How VIR is trading
Vir Biotechnology, Inc. is +126% over the past year while the S&P 500 is +18%: 108 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +31%
vs 200-day average · a clear uptrend
- RSI (14)
- 60
RSI (14) · neutral
- Below its 52-week high
- 0.64%
Below its 52-week high
Details›
- Last close2026-10-09
- $11.71
- 1 monthS&P 500 +2.7%
- +11%
- 1 yearS&P 500 +18%
- +126%
- 5 yearsS&P 500 +88%
- −77%
- vs 50-day average$10.37
- +13%
- 52-week high
- $11.78
- 52-week low
- $5.12
- Annualised volatility
- 78%
| Year | Return |
|---|---|
| 2026 (year to date) | +94% |
| 2025 | −18% |
| 2024 | −27% |
| 2023 | −60% |
| 2022 | −40% |
| 2021 | +56% |
| 2020 | +113% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 7 | 5 of 7 | +44% |
| Feb | 7 | 3 of 7 | +6.4% |
| Mar | 7 | 2 of 7 | −11% |
| Apr | 7 | 2 of 7 | −5.5% |
| May | 7 | 4 of 7 | +4.0% |
| Jun | 7 | 4 of 7 | +2.2% |
| Jul | 7 | 4 of 7 | −5.3% |
| Aug | 7 | 2 of 7 | +1.00% |
| Sep | 7 | 2 of 7 | −9.6% |
| Oct | 7 | 3 of 7 | −2.0% |
| Nov | 7 | 6 of 7 | +11% |
| Dec | 7 | 2 of 7 | −5.8% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.